Clinical trials: Chronic Infection With HIV
HIV-1 Infection
Targeting Platelets in Chronic HIV Infection
Advances in antiretroviral therapy (ART) have resulted in increased survival of the HIV-infected population; however, this gain in longevity is associated with an increased risk of cardiovascular disease (CVD).
- Trial name
- NCT02578706
- Testing
- Clopidogrel, Aspirin
- Where
- United States
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- Icahn School of Medicine at Mount Sinai
HIV
Phase I Study of HIV 1 Antigen Expanded Specific T Cell Therapy
This is a phase 1, single-site study is to evaluate the safety and immunologic and virologic efficacy of ex vivo expanded HIV-1 multi-antigen specific T-cell (HXTC) therapy in HIV-infected individuals with viral suppression on…
- Trial name
- HXTC (NCT02208167)
- Testing
- HXTC infusion
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- University of North Carolina, Chapel Hill
Hepatitis C, Chronic, HIV CDC Category A1
A Study of the Safety and Effectiveness of Simeprevir and Sofosbuvir for Patients With HIV and Hepatitis C
This is a study of the safety and effectiveness of the hepatitis C medications sofosbuvir and simeprevir in patients who have both the HIV and hepatitis C (HCV) viruses.
- Trial name
- NCT02206932
- Testing
- Sofosbuvir + Simeprevir
- Where
- United States
- Sponsor
- University of California, San Francisco
HIV Infections, HIV-1-infection
A Prospective Cohort for ex Vivo Cure Studies With Chronic HIV Infected Patients in the Netherlands
A prospective non-interventional cohort study at Erasmus MC of adult chronic HIV infected patients of ≥18 years of age who initiate antiretroviral therapy in routine care.
- Conditions
- HIV Infections, HIV-1-infection, HIV-2 Infection
- Trial name
- CHRONO (NCT04888754)
- Where
- Netherlands
- Volunteers
- 35 people
- Sponsor
- Erasmus Medical Center
Hepatitis C, Human Immunodeficiency Virus
Efficacy and Safety of Sofosbuvir Plus Ribavirin in Chronic Genotype 1, 2 and 3 Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV) Co-infected Adults
This study will evaluate the efficacy, safety, and tolerability of sofosbuvir (SOF; GS-7977) plus ribavirin (RBV) in adults with chronic genotypes 1, 2, and 3 HCV infection who are coinfected with HIV-1.
- Trial name
- NCT01667731
- Testing
- SOF, RBV
- Where
- 27 sites in United States, Puerto Rico
- Volunteers
- 224 people
- Sponsor
- Gilead Sciences
HIV, Coronary Artery Disease
Metformin for HIV Inflammation
This proposal seeks to assess the impact of 24 weeks of metformin on non-calcified plaques and calcified plaques assessed by coronary CT angiography, and on whether these changes can be explained by metformin-induced phenotypic…
- Trial name
- NCT02383563
- Testing
- metformin extended release
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- University of Hawaii
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV2), HIV
COVID-19 Recovery Study: Symptoms and Biomarkers of Long COVID-19 in People Living With and Without HIV
This observational study will prospectively characterize the long-term symptoms and side effects of COVID-19 in cohorts of people living with and without HIV.
- Trial name
- NCT04958889
- Testing
- No intervention
- Where
- United States
- Volunteers
- 392 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins University
HIV Infections
Study of the HIV gp120/NefTat/AS02A Vaccine to Treat Individuals With Chronic HIV-1 Infection on Highly Active Antiretroviral Therapy (HAART)
This study will test the safety and immunogenicity of the gp120/NefTat/AS02A vaccine candidate in individuals with chronic HIV-1 infection successfully treated with HAART.
- Trial name
- NCT00117429
- Testing
- HIV gp120/NefTat/AS02A Vaccine
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Marcus Altfeld, M.D., Ph.D.
HIV
Intermittent Versus Continuous HAART (Highly Active Antiretroviral Therapy) for Treating Chronic HIV Infected Patients in Uganda
Although highly active antiretroviral therapy (HAART) has been successful in suppressing plasma HIV RNA levels and providing significant clinical benefit in infected patients, it does not eradicate HIV infection.
- Trial name
- NCT00339456
- Testing
- HAART
- Where
- Uganda
- Volunteers
- 155 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
NSCLC Stage IV, HIV
Nivolumab/Ipilimumab and Chemotherapy Combination in Advanced NSCLC Patients With HIV, HBV, HCV and Long Covid Syndrome
Study type: Phase 2 - Interventional Trial Number of patients to be enrolled: 105 Participating countries: Italy Study drugs: nivolumab and ipilimumab Cohort A: HBV and HCV patients Cohort B: HIV patients Cohort C: Long COVID…
- Conditions
- NSCLC Stage IV, HIV, HBV, HCV
- Trial name
- LUNGVIR (NCT05597800)
- Testing
- Nivolumab and Ipilimumab
- Where
- Italy
- Volunteers
- 105 people
- Sponsor
- Universita di Verona
Chronic Hepatitis C
Study to Evaluate the Treatment for Chronic Hepatitis C With Normal Transaminases in HIV Positive Patients
In the current practice patients with normal levels of ALT were not treated. However, a percentage of patients will present an advanced grade of fibrosis and cirrhosis.
- Trial name
- CONTRA (NCT01684787)
- Testing
- Peginterferon alfa-2a + ribavirin in normal ALT, Peginterferon alfa-2a + ribavirin in elevated ALT
- Where
- 18 sites in Spain
- Volunteers
- 80 people
- Sponsor
- Miguel Santin
Acute HIV Infection, Chronic HIV Infection
Antiretroviral Therapy for Acute and Chronic HIV Infection
The purpose for this protocol is to provide safe and effective standard ART to SEARCH 010 and SEARCH 013 participants. Participants are enrolled in an acute HIV infection study (SEARCH 010 protocol: 'Establish and characterize an…
- Trial name
- AAHIV (NCT00796263)
- Testing
- HAART
- Where
- Thailand
- Volunteers
- 900 people
- Sponsor
- SEARCH Research Foundation
HCV Coinfection, HIV Infection
Efficacy of Pegylated Interferon Plus Ribavirin Plus Nitazoxanide in HCV Genotype 4 and HIV Coinfection
Objectives: 1. Primary objective: To Evaluate the rate of sustained virological response (SVR) of pegylated interferon alfa-2b (Peg-IFN) plus ribavirin (RBV) plus nitazoxanide (NTZ) in patients coinfected by HIV and HCV genotype…
- Trial name
- NCT01529073
- Testing
- Nitazoxanide
- Where
- Spain
- Volunteers
- 45 people
- Sponsor
- Juan Macías
HIV-1-infection, Hepatitis C, Chronic
Switch to Genvoya Followed by HCV Therapy With Epclusa Followed by Simplification of HIV Therapy With Biktarvy in Patients With HIV-HCV Co-Infected Subjects on Opioid Substitution Therapy
The study hypothesis is to determine the feasibility of switching HIV-HCV co-infected patients receiving methadone or buprenorphine/naloxone as opioid substitution therapy with suppressed HIV RNA viral load on current…
- Conditions
- HIV-1-infection, Hepatitis C, Chronic, Methadone Dependence, Opioid Dependence
- Trial name
- NCT03549312
- Testing
- Genvoya, Epclusa, Biktarvy
- Where
- Canada
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Saskatchewan Health Authority - Regina Area
HIV Infections
Vaccination With Autologous Dendritic Cells Pulsed With HIV-Antigens for Treatment of Patients With Chronic HIV-Infection
Phase I test of concept study: In an attempt to induce new immunity to HIV-1 during untreated HIV-1 infection the investigators have identified relatively immune silent immune subdominant HLA-A2-restricted HIV-1 CTL epitopes that…
- Trial name
- HIVDCVac (NCT00856154)
- Testing
- Peptides on autologous Dendritic Cells
- Where
- Denmark
- Volunteers
- 12 people
- Sponsor
- Statens Serum Institut
Chronic HIV Infection
Optimizing Viral Load Suppression in Kenyan Children on Antiretroviral Therapy
Among nearly 1 million HIV-infected children receiving antiretroviral treatment (ART), as many as 40% of those living in resource limited settings have not achieved virologic suppression.
- Trial name
- Opt4Kids (NCT03820323)
- Testing
- POC VL and targeted DRM testing., SOC VL testing
- Where
- Kenya
- Volunteers
- 704 people
- Sponsor
- University of Alabama at Birmingham
HIV-infection/AIDS
Vedolizumab Treatment in Antiretroviral Drug Treated Chronic HIV Infection
Background: In nearly all people with human immunodeficiency virus (HIV) infection, immunity cannot either control or eradicate the infection.
- Trial name
- HAVARTI (NCT03147859)
- Testing
- Vedolizumab (brand name Entyvio)
- Where
- Canada
- Volunteers
- 10 people
- Sponsor
- Ottawa Hospital Research Institute
Chronic Hepatitis C Infection in HIV-Infected Persons, HIV Infections
PEG-Interferon a-2b + Ribavirin for Treatment of Chronic HRN 005 Hepatitis C Infection in HIV-Infected Persons Not Previously Treated With Interferon
Objectives: Primary To compare the sustained virologic response (SVR) of PEGIntron plus ribavirin among patients receiving 48 weeks versus 72 weeks of therapy (defined as undetectable HCV RNA level 24 weeks after discontinuing…
- Trial name
- NCT00215891
- Testing
- PEG-Interferon a-2b + Ribavirin
- Where
- United States
- Volunteers
- 300 people
- Sponsor
- Hepatitis Resource Network
HIV Infections
Immune and Viral Outcomes of HIV-1 Therapy Interruption
The purpose of this study is to determine if stopping anti-HIV drugs for a period of time is safe and effective for enhancing the immune function of patients with HIV.
- Trial name
- NCT00051818
- Testing
- Treatment interruption/reinitiation schedule
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- The Wistar Institute
Frail in HIV Population
Search for Fragility Indicators Among People Aged 50+ With Chronic HIV Infection
The frailty and frail elderly was defined in 2001 by Fried as a physiological state of heightened vulnerability to external shocks. 5 criteria for classifying the elderly in 3 categories: frail, pre-frail and not frail.
- Trial name
- Visage 3 (NCT02874118)
- Testing
- Fried scale for frailty assessement
- Where
- France
- Volunteers
- 510 people
- Sponsor
- Assistance Publique Hopitaux De Marseille